Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) EBIAT: 2014-2020

Historic EBIAT for Larimar Therapeutics (LRMR) over the last 6 years, with Mar 2020 value amounting to -$3.6 million.

  • Larimar Therapeutics' EBIAT rose 72.56% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.67%. This contributed to the annual value of -$45.4 million for FY2019, which is 26.01% up from last year.
  • Per Larimar Therapeutics' latest filing, its EBIAT stood at -$3.6 million for Q1 2020, which was up 50.38% from -$7.3 million recorded in Q4 2019.
  • Larimar Therapeutics' 5-year EBIAT high stood at -$3.6 million for Q1 2020, and its period low was -$17.7 million during Q1 2016.
  • Moreover, its 3-year median value for EBIAT was -$13.1 million (2019), whereas its average is -$12.3 million.
  • Per our database at Business Quant, Larimar Therapeutics' EBIAT crashed by 31.65% in 2016 and then soared by 72.56% in 2020.
  • Quarterly analysis of 5 years shows Larimar Therapeutics' EBIAT stood at -$10.4 million in 2016, then fell by 25.35% to -$13.1 million in 2017, then decreased by 11.35% to -$14.6 million in 2018, then surged by 50.23% to -$7.3 million in 2019, then soared by 72.56% to -$3.6 million in 2020.
  • Its EBIAT stands at -$3.6 million for Q1 2020, versus -$7.3 million for Q4 2019 and -$12.9 million for Q3 2019.